¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ Ä¡¸ÅȯÀÚ¿¡°Ô ÀÎÁö±â´ÉÇâ»óÀ» À§ÇÑ ºñ°­ ³» Àν¶¸°(Intranasal Insulin) Åõ¿© È¿°ú
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

¾ËÃ÷ÇÏÀ̸Ó(Alzheimer's Disease) ȯÀÚ¿¡°Ô ÀÎÁö±â´É Çâ»óÀ» À§ÇÑ ºñ°­ ³» Àν¶¸°(Intranasal Insulin) Åõ¿© È¿°ú

 

ÀÓ»óÁú¹®

¾ËÃ÷ÇÏÀ̸Ó(Alzheimer's Disease, AD) ȯÀÚ¿¡°Ô ÀÎÁö±â´ÉÀúÇϸ¦ ¿¹¹æÇÏ´Â Ä¡·á ¿É¼ÇÀ¸·Î ºñ°­ ³» Àν¶¸°Åõ¿©°¡ È¿°úÀûÀԴϱî?

±Ù°Å±â¹Ý´äº¯

ºñ°­ ³» Àν¶¸°Àº ¾ËÃ÷ÇÏÀÌ¸Ó º´ ȯÀÚ¿¡¼­ ÀÎÁö±â´ÉÀ» Çâ»ó½ÃÅ°´Âµ¥ À¯ÀÍÇÑ È¿°ú¸¦ ³ªÅ¸³¾ ¼öÀÖÀ½À» º¸°íÇÏ¿´½À´Ï´Ù.

¼­ÁöÁ¤º¸

Intranasal Insulin for Alzheimer's Disease and Amnestic Mild Cognitive Impairment: Systematic Review and Meta-analysis (2017), Korean J Clin Pharm 2017;27:161-70 https://doi.org/10.24304/kjcp.2017.27.3.161

Áúº´Æ¯¼º

¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× °Ç¸ÁÁõ °æµµ ÀÎÁöÀå¾Ö

(Alzheimer's Disease and Amnestic Mild Cognitive Impairment)

¿¬±¸¼³°è

ü°èÀû °íÂû(Systematic Review) & ¸ÞŸºÐ¼® (Meta-Analysis)

¿¬±¸´ë»ó

360¸í : 146¸íÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× 214¸í °Ç¸ÁÁõ °æµµ ÀÎÁöÀå¾Ö(Mild Cognitive Impairment, MCI) ȯÀÚ¸¦ ´ë»óÀ¸·Î ÃÑ  7 RCTs

Ä¡·áÁßÀç

Intranasal Insulin (either 20 IU or 40 IU):: AD¿¡¼­ ÀÎÁö±â´ÉÀÇ ÀúÇϸ¦ ¿¹¹æÇÏ´Â Ä¡·á ¿É¼ÇÀ¸·Î ºñ°­ ³» Àν¶¸°(intranasal insulin) Åõ¿©¿Í Çö󼼺¸(placebo) ºñ±³

Æò°¡ÁöÇ¥

ÀÎÁö±â´É(Cognitive Function)

±â¾ï·Â Áõ°¡(Improving Memory)

±â¾ïº¸Á¸(Preserving Memory)

»ó¼¼¼³¸í

ºñ°­ ³» Àν¶¸°°ú À§¾à »çÀÌÀÇ ÀÏÂ÷ °á°ú¸¦ ºñ±³ ÇÑ ¿¬±¸¿¡¼­ ºñ°­ ³» Àν¶¸°À¸·Î Ä¡·á ÇÑ ±×·ì¿¡¼­ ±â¾ï·Â ¹× ±âŸ ³úÀÎÁö ±â´ÉÀÌ ÇöÀúÈ÷ Çâ»óµÇ¾úÀ½À» ³ªÅ¸³»¾ú½À´Ï´Ù( (standardized mean difference; SMD = 0.109; 95% confidence interval; CI -0.04 to 0.26; P=0.14).   Åõ¿©·®ÀÇ ºñ±³¿¡¼­´Â ºñ°­³» Àν¶¸°Åõ¿© 20 IU »ç¿ëÀÌ ÀÎÁö±â´ÉÇâ»ó¿¡ À¯ÀÇÇÑ °³¼±À» º¸¿´À¸³ª(SMD = 0.14; 95% CI 0.05 to 0.24; P=0.004) 40 IU´Â È¿°ú¸¦ ³ªÅ¸³»Áö ¾Ê¾Ò´Ù(SMD = -0.01; 95% CI -0.11 to 0.09; P=0.82).

±Ù°Å¼öÁØ

Moderate

ÀÛ¼ºÀÚ

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)

Copyright © 2015 Medical Research Information Center (MedRIC) Editors

 


2018-03-21 ¿ÀÀü 10:42:29, Á¶È¸¼ö : 2838